Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline

Abstract

Identifying individuals who have Lynch syndrome (LS) involves a complex diagnostic work up that includes taking a detailed family history and a combination of various genetic and immunohistochemical tests. The National Society of Genetic Counselors (NSGC) and the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC) have come together to publish this clinical practice testing guideline for the evaluation of LS. The purpose of this practice guideline is to provide guidance and a testing algorithm for LS as well as recommendations on when to offer testing. This guideline does not replace a consultation with a genetics professional. This guideline includes explanations in support of this and a summary of background data. While this guideline is not intended to serve as a review of LS, it includes a discussion of background information on LS, and cites a number of key publications which should be reviewed for a more in-depth understanding of LS. These guidelines are intended for genetic counselors, geneticists, gastroenterologists, surgeons, medical oncologists, obstetricians and gynecologists, nurses and other healthcare providers who evaluate patients for LS.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Backes, F. J., Leon, M. E., Ivanov, I., Suarez, A., Frankel, W. L., Hampel, H., et al. (2009). Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynaecological Oncology, 114, 486–490.

    Article  CAS  Google Scholar 

  2. Baglietto, L., Lindor, N. M., Dowty, J. G., White, D. M., Wagner, A., Gomez Garcia, E. B., et al. (2009). Risks of Lynch syndrome cancers for MSH6 mutation carriers. Journal of the National Cancer Institute, 102(3), 193–201.

    PubMed  Article  Google Scholar 

  3. Bao, F., Panarelli, N. C., Rennert, H., Sherr, D. L., & Yantiss, R. K. (2010). Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. The American Journal of Surgical Pathology, 34, 1798–1804.

    PubMed  Article  Google Scholar 

  4. Barrow, E., Alduaij, W., Robinson, L., Shenton, A., Clancy, T., Lalloo, F., et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 74(3), 233–242.

    PubMed  Article  CAS  Google Scholar 

  5. Boland, C. R. (2005). Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Familial Cancer, 4(3), 211–218.

    PubMed  Article  Google Scholar 

  6. Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., et al. (1998). A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Research, 58, 5248–5257.

    PubMed  CAS  Google Scholar 

  7. Capelle, L. G., Van Grieken, N. C., Lingsma, H. F., Steyerberg, E. W., Klokman, W. J., Bruno, M. J., et al. (2010). Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology, 138, 487–492.

    PubMed  Article  Google Scholar 

  8. Chang, D. K., Metzgar, D., Willis, C., & Boland, C. R. (2001). Microsatellites in the eukaryotic DNA mismatch repair genes as modulators of evolutionary mutation rate. Genome Research, 11, 1145–1146.

    PubMed  Article  CAS  Google Scholar 

  9. Chao, E. C., Velasquez, J. L., Witherspoon, M. S., Rozek, L. S., Peel, D., Ng, P., et al. (2008). Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Human Mutation, 29(6), 852–860.

    PubMed  Article  CAS  Google Scholar 

  10. Choi, M. Y., Lauwers, G. Y., Hur, C., Willett, C. G., & Chung, D. C. (2007). Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. International Journal of Radiation Oncology, Biology, and Physics, 68(5), 1584.

    Article  Google Scholar 

  11. Clendenning, M., Hampel, H., LaJeunesse, J., Lindblom, A., Lockman, J., Nilbert, M., et al. (2006). Long-range PCR facilitates the identification of PMS2-specific mutations. Human Mutation, 27, 490–495.

    PubMed  Article  CAS  Google Scholar 

  12. De Jong, A. E., van Puijenbroek, M., Hendriks, Y., Tops, C., Wijnen, J., Ausems, M. G., et al. (2004). Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clinical Cancer Research, 10(3), 972–980.

    PubMed  Article  Google Scholar 

  13. Evaluation of Genomic Applications in Practice and Prevention Working Group. (2009). Recommendations from the EGAPP working group: genetic testing strategies in the newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.

    Article  Google Scholar 

  14. Garg, K., Leitao, M. M., Kauff, N. D., Hansen, J., Kosarin, K., Shia, J., et al. (2009). Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. The American Journal of Surgical Pathology, 33, 925–933.

    PubMed  Article  Google Scholar 

  15. Hampel, H. (2010). Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. Journal of the National Comprehensive Cancer Network, 8, 597–601.

    PubMed  Google Scholar 

  16. Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2005a). Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). The New England Journal of Medicine, 352(18), 1851–1860.

    Article  CAS  Google Scholar 

  17. Hampel, H., Stephens, J. A., Pukkala, E., Sankila, R., Aaltonen, L. A., Mecklin, J. P., et al. (2005b). Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology, 129(2), 415–421.

    Google Scholar 

  18. Hampel, H., Frankel, W., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., et al. (2006). Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among EC patients. Cancer Research, 66(15), 7810–7817.

    PubMed  Article  CAS  Google Scholar 

  19. Hampel, H., Panescu, J., Lockman, J., Sotamaa, K., Fix, D., Comeras, I., et al. (2007). Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Research, 67(19), 9603.

    PubMed  Article  CAS  Google Scholar 

  20. Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. (2008). Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Journal of Clinical Oncology, 26(35), 5783–5788.

    PubMed  Article  Google Scholar 

  21. Hitchins, M. P., & Ward, R. L. (2009). Constitutional (germline) MLH1 epimutation as an aetiological mechanism for hereditary non-polyposis colorectal cancer. Journal of Medical Genetics, 46(12), 793–802.

    PubMed  Article  CAS  Google Scholar 

  22. Hitchins, M. P., Rapkins, R. W., Kwok, C., Srivastava, S., Wong, J. J. L., Khachigian, L. M., et al. (2011). Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant with the 5′UTR. Cancer Cell, 20, 200–213.

    PubMed  Article  CAS  Google Scholar 

  23. Jass, J. R. (2006). Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World Journal of Gastroenterology, 12(31), 4943–4950.

    PubMed  CAS  Google Scholar 

  24. Kuiper, R. P., Vissers, L. E. L. M., Venkatachalam, R., Bodmer, D., Hoenselaar, E., Goossens, M., et al. (2011). Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Human Mutation, 32(4), 407–414.

    PubMed  Article  CAS  Google Scholar 

  25. Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., Boland, C. R., et al. (2011). Strategies to identify Lynch syndrome among patients with colorectal cancer: a cost effective analysis. Annals of Internal Medicine, 155(2), 69–79.

    PubMed  Google Scholar 

  26. Lightenberg, M. J., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., et al. (2009). Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nature Genetics, 41, 112–117.

    Article  Google Scholar 

  27. Lindor, N. M. (2009). Familial colon cancer type X: the other half of hereditary non polyposis colorectal cancer syndrome. Surgical Oncology Clinics of North America, 18, 637–645.

    PubMed  Article  Google Scholar 

  28. Lindor, N. M., Burgart, L. J., Leontovich, O., Goldberg, R. M., Cunningham, J. M., Sargent, D., et al. (2002). Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. Journal of Clinical Oncology, 20, 1043–1048.

    PubMed  Article  CAS  Google Scholar 

  29. Lindor, N. M., Rabe, K., Petersen, G. M., Haile, R., Casey, G., Baron, J., et al. (2005). Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. Journal of the American Medical Association, 293(16), 1979–1985.

    PubMed  Article  CAS  Google Scholar 

  30. Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., et al. (2006). Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. Journal of the American Medical Association, 296(12), 1507–1517.

    PubMed  Article  CAS  Google Scholar 

  31. Loughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Kovalenko, S., Beshay, V., et al. (2007). Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Familial Cancer, 6(3), 301–310.

    PubMed  Article  CAS  Google Scholar 

  32. Modica, I., Soslow, R. A., Black, D., Tornos, C., Kauff, N., & Shia, J. (2007). Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. American Journal of Surgical Pathology, 31, 744–751.

    PubMed  Article  Google Scholar 

  33. Müller, A., Giuffre, G., Edmonston, T. B., Mathiak, M., Roggendorf, B., Heinmöller, E., et al. (2004). Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. Journal of Molecular Diagnostics, 6, 308–315.

    PubMed  Article  Google Scholar 

  34. Mvundura, M., Grosse, S. D., Hampel, H., & Palomaki, G. E. (2010). The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genetics in Medicine, 12(2), 93–104.

    PubMed  Article  Google Scholar 

  35. Nakagawa, H., Lockman, J. C., Frankel, W. L., Hampel, H., Steenblock, K., Burgart, L. J., et al. (2004). Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Research, 64(14), 4721–4727.

    PubMed  Article  CAS  Google Scholar 

  36. Niessen, R. C., Kleibeuker, J. H., Westers, H., Jager, P. O., Rozeveld, D., Bos, K. K., et al. (2009a). PMS2 involvement in patients suspected of Lynch syndrome. Genes, Chromosomes & Cancer, 48(4), 322–329.

    Article  CAS  Google Scholar 

  37. Niessen, R. C., Hofstra, R. M. W., Westers, H., Lightenberg, M. J. L., Kooi, K., Jager, P. O. J., et al. (2009b). Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes, Chromosomes & Cancer, 48, 737–744.

    Article  CAS  Google Scholar 

  38. Palomaki, G. E., McClain, M. R., Melillo, S., Hampel, H., & Thibodeau, S. N. (2009). EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine, 11(1), 42–65.

    PubMed  Article  Google Scholar 

  39. Peltomaki, P., & Vasen, H. (2004). Mutations associated with HNPCC predisposition—Update of ICG-HNPCC/INSiGHT mutation database. Disease Markers, 20(4–5), 269–276.

    PubMed  Google Scholar 

  40. Plaschke, J., Engel, C., Kruger, S., Holinski-Feder, E., Pagenstecher, C., Mangold, E., et al. (2004). Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. Journal of Clinical Oncology, 22(22), 4486–4494.

    PubMed  Article  CAS  Google Scholar 

  41. Rijcken, F. E., Hollema, H., & Kleibeuker, J. H. (2002). Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation. Gut, 50, 382–386.

    PubMed  Article  CAS  Google Scholar 

  42. Senter, L., Clendenning, M., Sotamaa, K., Hampel, H., Green, J., Potter, J. D., et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419–428.

    PubMed  Article  CAS  Google Scholar 

  43. Shia, J., Tang, L. H., Vakiani, E., Guillem, J. G., Stadler, Z. K., Soslow, R. A., et al. (2009). Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary non-polyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. American Journal of Surgical Pathology, 33, 1639–1645.

    PubMed  Article  Google Scholar 

  44. Simpkins, S. B., Bocker, T., Swisher, E. M., Mutch, D. G., Gersell, D. J., Kovatich, A. J., et al. (1999). MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Human Molecular Genetics, 8(4), 661–666.

    PubMed  Article  CAS  Google Scholar 

  45. Stoffel, E., Mukherjee, B., Raymond, V. M., Tayob, N., Kastrinos, F., Sparr, J., et al. (2009). Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology, 137(5), 1621–1627.

    PubMed  Article  Google Scholar 

  46. The NCCN Clinical Practice Guidelines in Oncology™ Colorectal Cancer Screening Version 2.2011 (2011) National Comprehensive Cancer Network, Inc. Retrieved from http://www.nccn.org.

  47. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., et al. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261–268.

    PubMed  Article  CAS  Google Scholar 

  48. Vasen, H. F., Mecklin, J. P., Khan, P. M., & Lynch, H. T. (1991). The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Diseases of the Colon & Rectum, 34(5), 424–425.

    Article  CAS  Google Scholar 

  49. Vasen, H. F., Mecklin, J. P., Khan, P. M., & Lynch, H. T. (1994). The International Collaborative Group on HNPCC. Anticancer Research, 14, 1661–1664.

    PubMed  CAS  Google Scholar 

  50. Vasen, H. F., Watson, P., Mecklin, J. P., & Lynch, H. T. (1999). New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 116(6), 1453–1456.

    PubMed  Article  CAS  Google Scholar 

  51. Vaughn, C. P., Robles, J., Swensen, J. J., Miller, C. E., Lyon, E., Mao, R., et al. (2010). Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes. Human Mutation, 31, 588–593.

    PubMed  CAS  Google Scholar 

  52. Wang, L., Cunningham, J. M., Winters, J. L., Guenther, J. C., French, A. J., Boardman, L. A., et al. (2003). BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Research, 63(17), 5209–5212.

    PubMed  CAS  Google Scholar 

  53. Watson, P., Vasen, H. F., Mecklin, J. P., Bernstein, I., Aarnio, M., Järvinen, H. J., et al. (2008). The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. International Journal of Cancer, 123, 444–449.

    Article  CAS  Google Scholar 

  54. Weissman, S. M., Bellcross, C., Chimera Bittner, C., Freivogel, M. E., Larsen Haidle, J., Kaurah, P., et al. (2011). Genetic counseling considerations in the evaluation of families with Lynch syndrome—a review. Journal of Genetic Counseling, 20(1), 5–19.

    PubMed  Article  Google Scholar 

  55. Wimmer, K., & Etzler, J. (2008). Constitutional mismatch repair deficiency syndrome: have we so far seen only the tip of the iceberg? Human Genetics, 2008(124), 105–122.

    Article  Google Scholar 

  56. Zighelboim, I., Powell, M., Babb, S., Whelan, A., Schmidt, A., Clendenning, M., et al. (2009). Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. FamCancer, 8(4), 501–504.

    CAS  Google Scholar 

Download references

Disclaimer

This practice guideline was developed by members of the NSGC and CGA-ICC to assist genetic counselors and other health care providers in making decisions about appropriate management of genetic concerns; including access to and/or delivery of services. This practice guideline focuses on a clinical or practice-based issue, and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within this joint NSGC and CGA-ICC practice guideline reflect scientific and clinical knowledge current as of the time of publication, is only current as of its publication date, and is subject to change without notice as advances emerge.

In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health care provider’s best medical judgment based on the clinical circumstances of a particular patient or patient population. This practice guideline is published by NSGC and CGA-ICC for educational and informational purposes only, and neither NSGC nor CGA-ICC “approves” or “endorses” any specific methods, practices, or sources of information contained herein.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Scott M. Weissman.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Weissman, S.M., Burt, R., Church, J. et al. Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. J Genet Counsel 21, 484–493 (2012). https://doi.org/10.1007/s10897-011-9465-7

Download citation

Keywords

  • Lynch syndrome
  • Colorectal neoplasms
  • Microsatellite instability
  • Immunohistochemistry
  • Practice guideline
  • DNA mismatch repair
  • Genetic testing
  • Uterine neoplasms